Annual CFO
-$3.14 M
+$11.77 M+78.92%
April 30, 2024
Summary
- As of March 10, 2025, IPA annual cash flow from operations is -$3.14 million, with the most recent change of +$11.77 million (+78.92%) on April 30, 2024.
- During the last 3 years, IPA annual CFO has fallen by -$2.69 million (-585.74%).
- IPA annual CFO is now -104703.33% below its all-time high of -$3000.00, reached on December 31, 2015.
Performance
IPA Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$1.65 M
-$315.40 K-23.69%
October 31, 2024
Summary
- As of March 10, 2025, IPA quarterly cash flow from operations is -$1.65 million, with the most recent change of -$315.40 thousand (-23.69%) on October 31, 2024.
- Over the past year, IPA quarterly CFO has dropped by -$315.40 thousand (-23.69%).
- IPA quarterly CFO is now -548.29% below its all-time high of $367.40 thousand, reached on April 30, 2020.
Performance
IPA Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$5.70 M
-$1.64 M-40.39%
October 31, 2024
Summary
- As of March 10, 2025, IPA TTM cash flow from operations is -$5.70 million, with the most recent change of -$1.64 million (-40.39%) on October 31, 2024.
- Over the past year, IPA TTM CFO has dropped by -$1.64 million (-40.39%).
- IPA TTM CFO is now -688.42% below its all-time high of $969.10 thousand, reached on October 31, 2020.
Performance
IPA TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
IPA Cash From Operations Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +78.9% | -23.7% | -40.4% |
| 3 y3 years | -585.7% | -23.7% | -40.4% |
| 5 y5 years | -29.2% | -23.7% | -40.4% |
IPA Cash From Operations Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -585.7% | +78.9% | <-9999.0% | +79.4% | -86.9% | +64.6% |
| 5 y | 5-year | -585.7% | +78.9% | -548.3% | +79.4% | -688.4% | +64.6% |
| alltime | all time | <-9999.0% | +78.9% | -548.3% | +79.4% | -688.4% | +64.6% |
ImmunoPrecise Antibodies Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Oct 2024 | - | -$1.65 M(+23.7%) | -$5.70 M(+40.4%) |
| Jul 2024 | - | -$1.33 M(-32.0%) | -$4.06 M(+29.2%) |
| Apr 2024 | -$3.14 M(-78.9%) | -$1.96 M(+155.4%) | -$3.14 M(+3.1%) |
| Jan 2024 | - | -$766.40 K(>+9900.0%) | -$3.05 M(-36.1%) |
| Oct 2023 | - | -$6300.00(-98.5%) | -$4.78 M(-34.8%) |
| Jul 2023 | - | -$414.10 K(-77.8%) | -$7.32 M(-50.9%) |
| Apr 2023 | -$14.91 M(+88.6%) | -$1.86 M(-25.2%) | -$14.91 M(+2.6%) |
| Jan 2023 | - | -$2.49 M(-2.3%) | -$14.54 M(-9.7%) |
| Oct 2022 | - | -$2.55 M(-68.1%) | -$16.10 M(+6.4%) |
| Jul 2022 | - | -$8.01 M(+438.1%) | -$15.13 M(+91.3%) |
| Apr 2022 | -$7.91 M(+1624.5%) | -$1.49 M(-63.3%) | -$7.91 M(+13.3%) |
| Jan 2022 | - | -$4.05 M(+156.1%) | -$6.98 M(+101.3%) |
| Oct 2021 | - | -$1.58 M(+101.4%) | -$3.47 M(+124.9%) |
| Jul 2021 | - | -$785.30 K(+40.2%) | -$1.54 M(+236.3%) |
| Apr 2021 | -$458.50 K(-56.0%) | -$560.30 K(+3.7%) | -$458.50 K(-197.7%) |
| Jan 2021 | - | -$540.20 K(-257.2%) | $469.20 K(-51.6%) |
| Oct 2020 | - | $343.70 K(+15.2%) | $969.10 K(-273.0%) |
| Jul 2020 | - | $298.30 K(-18.8%) | -$560.30 K(-46.2%) |
| Apr 2020 | -$1.04 M(-57.2%) | $367.40 K(-1011.7%) | -$1.04 M(-50.3%) |
| Jan 2020 | - | -$40.30 K(-96.6%) | -$2.10 M(-15.7%) |
| Oct 2019 | - | -$1.19 M(+546.9%) | -$2.49 M(-0.3%) |
| Jul 2019 | - | -$183.30 K(-73.3%) | -$2.49 M(+2.5%) |
| Apr 2019 | -$2.43 M(-9.1%) | -$686.50 K(+59.5%) | -$2.43 M(+2.9%) |
| Jan 2019 | - | -$430.50 K(-63.9%) | -$2.36 M(+4.0%) |
| Oct 2018 | - | -$1.19 M(+872.0%) | -$2.27 M(+20.0%) |
| Jul 2018 | - | -$122.80 K(-80.1%) | -$1.89 M(-29.3%) |
| Apr 2018 | -$2.68 M(+367.3%) | -$617.30 K(+82.3%) | -$2.68 M(+30.0%) |
| Jan 2018 | - | -$338.60 K(-58.5%) | -$2.06 M(+19.7%) |
| Oct 2017 | - | -$815.60 K(-10.0%) | -$1.72 M(+86.6%) |
| Jul 2017 | - | -$906.00 K(+5357.8%) | -$922.60 K(+5424.6%) |
| Apr 2017 | -$572.90 K(>+9900.0%) | - | - |
| Sep 2016 | - | -$16.60 K(-2471.4%) | -$16.70 K(+882.4%) |
| Jun 2016 | - | $700.00(-275.0%) | -$1700.00(+183.3%) |
| Mar 2016 | - | -$400.00(0.0%) | -$600.00(-79.3%) |
| Dec 2015 | -$3000.00(-90.8%) | - | - |
| Dec 2015 | - | -$400.00(-75.0%) | -$2900.00(-107.1%) |
| Sep 2015 | - | -$1600.00(-188.9%) | $40.60 K(-825.0%) |
| Jun 2015 | - | $1800.00(-166.7%) | -$5600.00(+60.0%) |
| Mar 2015 | - | -$2700.00(-106.3%) | -$3500.00(-89.3%) |
| Dec 2014 | -$32.70 K(-72.3%) | - | - |
| Dec 2014 | - | $43.10 K(-190.2%) | -$32.70 K(-90.1%) |
| Sep 2014 | - | -$47.80 K(-1325.6%) | -$329.10 K(+225.2%) |
| Jun 2014 | - | $3900.00(-112.2%) | -$101.20 K(+2.7%) |
| Mar 2014 | - | -$31.90 K(-87.4%) | -$98.50 K(-16.6%) |
| Dec 2013 | -$118.10 K(+2646.5%) | - | - |
| Dec 2013 | - | -$253.30 K(-240.6%) | -$118.10 K(-184.8%) |
| Sep 2013 | - | $180.10 K(+2628.8%) | $139.30 K(-365.3%) |
| Jun 2013 | - | $6600.00(-112.8%) | -$52.50 K(-0.2%) |
| Mar 2013 | - | -$51.50 K(-1356.1%) | -$52.60 K(+1123.3%) |
| Dec 2012 | -$4300.00(-96.9%) | - | - |
| Dec 2012 | - | $4100.00(-135.0%) | -$4300.00(-97.8%) |
| Sep 2012 | - | -$11.70 K(-280.0%) | -$197.50 K(+1.3%) |
| Jun 2012 | - | $6500.00(-303.1%) | -$195.00 K(-12.5%) |
| Mar 2012 | - | -$3200.00(-98.3%) | -$222.80 K(+61.2%) |
| Dec 2011 | -$138.20 K(-97.3%) | - | - |
| Dec 2011 | - | -$189.10 K(+1955.4%) | -$138.20 K(-97.2%) |
| Sep 2011 | - | -$9200.00(-56.8%) | -$4.98 M(+0.7%) |
| Jun 2011 | - | -$21.30 K(-126.2%) | -$4.94 M(-0.7%) |
| Mar 2011 | - | $81.40 K(-101.6%) | -$4.98 M(-2.7%) |
| Dec 2010 | -$5.11 M(+1851.8%) | - | - |
| Dec 2010 | - | -$5.03 M(<-9900.0%) | -$5.11 M(+2650.8%) |
| Sep 2010 | - | $27.40 K(-148.9%) | -$185.90 K(-21.3%) |
| Jun 2010 | - | -$56.00 K(+1.3%) | -$236.20 K(+9.6%) |
| Mar 2010 | - | -$55.30 K(-45.8%) | -$215.50 K(-17.7%) |
| Dec 2009 | -$262.00 K | - | - |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2009 | - | -$102.00 K(+345.4%) | -$262.00 K(-51.6%) |
| Sep 2009 | - | -$22.90 K(-35.1%) | -$541.50 K(+253.2%) |
| Jun 2009 | - | -$35.30 K(-65.3%) | -$153.30 K(-23.5%) |
| Mar 2009 | - | -$101.80 K(-73.3%) | -$200.40 K(+36.7%) |
| Dec 2008 | -$146.60 K(-70.1%) | - | - |
| Dec 2008 | - | -$381.50 K(-204.4%) | -$146.60 K(-173.6%) |
| Sep 2008 | - | $365.30 K(-543.3%) | $199.30 K(-182.5%) |
| Jun 2008 | - | -$82.40 K(+71.7%) | -$241.60 K(-28.6%) |
| Mar 2008 | - | -$48.00 K(+34.8%) | -$338.20 K(-30.9%) |
| Dec 2007 | -$489.60 K(+86.8%) | - | - |
| Dec 2007 | - | -$35.60 K(-52.9%) | -$489.60 K(-30.7%) |
| Sep 2007 | - | -$75.60 K(-57.8%) | -$706.80 K(+152.2%) |
| Jun 2007 | - | -$179.00 K(-10.2%) | -$280.30 K(-17.8%) |
| Mar 2007 | - | -$199.40 K(-21.1%) | -$341.10 K(+30.1%) |
| Dec 2006 | -$262.10 K(+187.1%) | - | - |
| Dec 2006 | - | -$252.80 K(-172.0%) | -$262.10 K(+9.5%) |
| Sep 2006 | - | $350.90 K(-246.3%) | -$239.40 K(-56.1%) |
| Jun 2006 | - | -$239.80 K(+99.2%) | -$545.20 K(+348.7%) |
| Mar 2006 | - | -$120.40 K(-47.7%) | -$121.50 K(+33.1%) |
| Dec 2005 | -$91.30 K(+44.2%) | - | - |
| Dec 2005 | - | -$230.10 K(-610.2%) | -$91.30 K(-303.8%) |
| Sep 2005 | - | $45.10 K(-75.5%) | $44.80 K(+40.0%) |
| Jun 2005 | - | $183.90 K(-303.9%) | $32.00 K(-117.6%) |
| Mar 2005 | - | -$90.20 K(-4.0%) | -$182.10 K(+187.7%) |
| Dec 2004 | -$63.30 K(-50.5%) | - | - |
| Dec 2004 | - | -$94.00 K(-391.0%) | -$63.30 K(+497.2%) |
| Sep 2004 | - | $32.30 K(-207.0%) | -$10.60 K(-86.2%) |
| Jun 2004 | - | -$30.20 K(-205.6%) | -$76.70 K(+24.9%) |
| Mar 2004 | - | $28.60 K(-169.2%) | -$61.40 K(-52.0%) |
| Dec 2003 | -$127.80 K(+19.1%) | - | - |
| Dec 2003 | - | -$41.30 K(+22.2%) | -$127.80 K(+18.8%) |
| Sep 2003 | - | -$33.80 K(+126.8%) | -$107.60 K(+3.0%) |
| Jun 2003 | - | -$14.90 K(-60.6%) | -$104.50 K(-41.6%) |
| Mar 2003 | - | -$37.80 K(+79.1%) | -$178.90 K(+66.7%) |
| Dec 2002 | -$107.30 K(-40.7%) | - | - |
| Dec 2002 | - | -$21.10 K(-31.3%) | -$107.30 K(+55.7%) |
| Sep 2002 | - | -$30.70 K(-65.6%) | -$68.90 K(-127.5%) |
| Jun 2002 | - | -$89.30 K(-364.2%) | $250.20 K(-399.6%) |
| Mar 2002 | - | $33.80 K(+95.4%) | -$83.50 K(-53.9%) |
| Dec 2001 | -$181.00 K(+3190.9%) | - | - |
| Dec 2001 | - | $17.30 K(-94.0%) | -$181.00 K(+17.6%) |
| Sep 2001 | - | $288.40 K(-168.2%) | -$153.90 K(-66.1%) |
| Jun 2001 | - | -$423.00 K(+564.1%) | -$453.50 K(+825.5%) |
| Mar 2001 | - | -$63.70 K(-243.5%) | -$49.00 K(+790.9%) |
| Dec 2000 | -$5500.00(-96.1%) | - | - |
| Dec 2000 | - | $44.40 K(-496.4%) | -$5500.00(-88.9%) |
| Sep 2000 | - | -$11.20 K(-39.5%) | -$49.70 K(-43.1%) |
| Jun 2000 | - | -$18.50 K(-8.4%) | -$87.40 K(-20.8%) |
| Mar 2000 | - | -$20.20 K(<-9900.0%) | -$110.30 K(-21.4%) |
| Dec 1999 | -$140.40 K(+2.5%) | - | - |
| Dec 1999 | - | $200.00(-100.4%) | -$140.40 K(-15.4%) |
| Sep 1999 | - | -$48.90 K(+18.1%) | -$165.90 K(+8.3%) |
| Jun 1999 | - | -$41.40 K(-17.7%) | -$153.20 K(-2.4%) |
| Mar 1999 | - | -$50.30 K(+98.8%) | -$156.90 K(+14.6%) |
| Dec 1998 | -$137.00 K(-16.4%) | - | - |
| Dec 1998 | - | -$25.30 K(-30.1%) | -$136.90 K(-16.3%) |
| Sep 1998 | - | -$36.20 K(-19.7%) | -$163.60 K(+25.2%) |
| Jun 1998 | - | -$45.10 K(+48.8%) | -$130.70 K(+109.1%) |
| Mar 1998 | - | -$30.30 K(-41.7%) | -$62.50 K(-61.9%) |
| Dec 1997 | -$163.90 K(+106.7%) | - | - |
| Dec 1997 | - | -$52.00 K(+1475.8%) | -$164.00 K(+46.4%) |
| Sep 1997 | - | -$3300.00(-114.3%) | -$112.00 K(+3.0%) |
| Jun 1997 | - | $23.10 K(-117.5%) | -$108.70 K(-17.5%) |
| Mar 1997 | - | -$131.80 K | -$131.80 K |
| Dec 1996 | -$79.30 K | - | - |
FAQ
- What is ImmunoPrecise Antibodies annual cash flow from operations?
- What is the all time high annual CFO for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies annual CFO year-on-year change?
- What is ImmunoPrecise Antibodies quarterly cash flow from operations?
- What is the all time high quarterly CFO for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies quarterly CFO year-on-year change?
- What is ImmunoPrecise Antibodies TTM cash flow from operations?
- What is the all time high TTM CFO for ImmunoPrecise Antibodies?
- What is ImmunoPrecise Antibodies TTM CFO year-on-year change?
What is ImmunoPrecise Antibodies annual cash flow from operations?
The current annual CFO of IPA is -$3.14 M
What is the all time high annual CFO for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high annual cash flow from operations is -$3000.00
What is ImmunoPrecise Antibodies annual CFO year-on-year change?
Over the past year, IPA annual cash flow from operations has changed by +$11.77 M (+78.92%)
What is ImmunoPrecise Antibodies quarterly cash flow from operations?
The current quarterly CFO of IPA is -$1.65 M
What is the all time high quarterly CFO for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high quarterly cash flow from operations is $367.40 K
What is ImmunoPrecise Antibodies quarterly CFO year-on-year change?
Over the past year, IPA quarterly cash flow from operations has changed by -$315.40 K (-23.69%)
What is ImmunoPrecise Antibodies TTM cash flow from operations?
The current TTM CFO of IPA is -$5.70 M
What is the all time high TTM CFO for ImmunoPrecise Antibodies?
ImmunoPrecise Antibodies all-time high TTM cash flow from operations is $969.10 K
What is ImmunoPrecise Antibodies TTM CFO year-on-year change?
Over the past year, IPA TTM cash flow from operations has changed by -$1.64 M (-40.39%)